Warfarin Versus Dabigatran: Comparing the Old with the New
Warfarin is an oral anticoagulant for treatment and prevention of venous and arterial thromboembolism. It requires regular monitoring and patient adherence to a variety of lifestyle factors that can influence its effect. Dabigatran is an oral direct thrombin-inhibitor recently approved
for stroke prevention in atrial fibrillation. The primary advantages of dabigatran are freedom from monitoring, a short duration of action, and a limited number of factors influencing its effect. Primary disadvantages of dabigatran compared with warfarin are that less is known about its use,
cost, and poor gastrointestinal tolerability. Clinical studies have revealed both agents to be effective, with comparable rates for major bleeding. Divergent recommendations have been offered by consensus guidelines. A patient-specific approach involving the perspectives of informed patients
is most reasonable.
Keywords: Anticoagulants; Atrial fibrillation; Benzimidazoles; Dabigatran; Oral anticoagulants; Stroke; Warfarin
Document Type: Research Article
Publication date: 01 February 2012
- The Consultant Pharmacist® is the official peer-reviewed journal of the American Society of Consultant Pharmacists. It is dedicated exclusively to the medication needs of the elderly in all settings, including adult day care, ambulatory care, assisted living, community, hospice, and nursing facilities. This award-winning journal is a member benefit of ASCP. Individuals who are not members and wish to receive The Consultant Pharmacist® will want to consider joining ASCP.
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Membership Information
- Information for Advertisers
- ">
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content